JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- Celltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) in adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC) after induction with intravenous (IV) infliximab, further supporting the efficacy and safety seen in previous pivotal studies. The data was shared during 18 oral and poster presentations at the Digestive Disease Week® (DDW) 2024 Annual Meeting in Washington, D.C., from May 18 to 21.
JERSEY CITY, N.J., April 28, 2024 /PRNewswire/ -- Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective April 4, 2024 provides ZYMFENTRA Preferred Brand Access on the Express Scripts National Preferred Formulary serving 21.9 Million insured lives. Express Scripts provides plan participants such as Health Plans of the PBM the ability to add ZYMFENTRA™ (infliximab-dyyb) to their formularies.
Advanced Infliximab Model Now Available from DoseMe
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Lynx.MD Leveraged for Study on Infliximab Optimization for IBD to be Presented
Pfizer`s Biologic IIxifi (Infliximab) Receives Approval in the U.S.
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA
Celltrion`s Biologic Zymfentra (infliximab) Receives Approval in the U.S.
Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease
A Pennsylvania federal judge on Wednesday cemented a $25 million settlement in a class action suit alleging Johnson & Johnson blocked biosimilar competition to its immunosuppressive drug Remicade.